Top 5 Most-Read AML Content of 2025

The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted therapies, the promise of off-the-shelf chimeric antigen receptor (CAR) T-cell treatments, and strategies to improve patient access to sophisticated care.

Research from annual meetings of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), and the European Hematology Association (EHA) highlighted the efficacy of new inhibitors for specific genetic alterations, real-world outcomes in pediatric AML, and practical ways to deliver high-quality innovations to more patients through academic-community partnerships.

Here is the most-read coverage of the latest news in 2025 for AML, and you can read all of our coverage here.

5. Academic-Community Partnerships Bringing Cancer Care to Patients

Research presented at the ASCO 2025 annual meeting examined how collaborations between academic institutions and community cancer centers can maintain high-quality care while significantly reducing the travel burden for patients. One abstract detailed a partnership for successfully delivering high-dose cytarabine consolidation, with outcomes comparable between the institution and the collaborating community cancer centers. The second abstract showed that implementing an academic precision oncology service in a community setting significantly increased next-generation sequencing testing rates.

Read the full article.

4. Quality Improvement Project Enhances AML Genomic Testing Efficiency

As AML classification increasingly relies on identifying distinct genetic subtypes, timely diagnostic results are critical. Research published in JCO Oncology Practice found that implementing a flow cytometry–triggered genomic testing algorithm with automated laboratory workflows facilitated faster, more informed treatment decisions by significantly reducing turnaround times. The quality improvement project was conducted at the London Health Science Centre, which utilized a multidisciplinary core working group to review clinical guidelines and AML therapies and identify ideal turnaround times for diagnostic tests before developing the genomic testing algorithm.

The initiative successfully reduced turnaround times for next-generation sequencing and NPM1 testing, allowing clinicians to make faster, more informed, personalized treatment decisions.

Read the full article.

3. Studies Examine Real-World Pediatric AML Treatment and Outcomes

This article, published in early January 2025, covered 2 posters presented a month earlier at the American Society of Hematology 2024 annual meeting that provided real-world outcomes data on pediatric AML. One retrospective analysis demonstrated that allogeneic hematopoietic cell transplantation significantly improved survival, particularly for patients in their first complete remission. The second poster evaluated data from the APAL2020SC PedAL trial for children with relapsed or refractory AML who were not in clinical trials. The research revealed a high prevalence of KMT2A fusions and identified effective reinduction regimens.

Read the full article.

2. For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone

While CAR T-cell therapy has been lifesaving in some blood cancers, these custom treatments can take weeks to manufacture—precious time that some patients don’t have. However, "off-the-shelf" allogeneic CAR T-cell therapies that can be created in advance from a healthy donor’s cells hold promise.

In part 1 of an interview, Stephen Strickland, MD, MSCI, discussed the potential of SENTI-202, an allogeneic CAR natural killer cell therapy. The results from a phase 1 trial presented at AACR showed scientists are getting close. Cancer suppresses the patient’s immune system, which can happen in many ways, but one way is thought to be through suppressing T cells’ ability to attack the cancer.

“By using healthy donor cells, we can get around that and make sure that we have a good, strong cellular product that isn't impacted by the things that led to the cancer evading the immune system in the first place,” Strickland explained.

Read the first part of the interview.

Read the second part of the interview.

1. Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

At the EHA Congress, research on revumenib (Revuforj; Syndax Pharmaceuticals) showed clinically meaningful responses in heavily pretreated populations with relapsed or refractory AML with NPM1 mutation, KMT2A rearrangement, and NUP98 rearrangement. Updated results from the AUGMENT-101 study highlighted a 26% complete response plus complete response with partial hematology recovery (CR + CRh) rate in patients with NPM1-mutated AML. In patients with KMT2Ar acute leukemia, the CR + CRh rate was 22.7%.

At the time, revumenib was only approved by the FDA to treat R/R AML with KMT2A translocation. Since the data were presented at EHA, the FDA approved revumenib for patients 1 year and older with R/R AML with a susceptible NPM1 mutation.

Read the full article.